Acelyrin Inc. announced on May 21, 2025, that it has completed a merger resulting in a change of control, making it a wholly owned subsidiary of Alumis. As part of this transition, Acelyrin notified Nasdaq of the merger's completion and requested the suspension of its common stock trading. The company plans to delist its stock from Nasdaq and deregister under the Securities Exchange Act of 1934. Additionally, Acelyrin intends to terminate its reporting obligations under the Exchange Act. This regulatory change is accompanied by the termination of its 2023 Employee Stock Purchase Plan.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。